<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04549623</url>
  </required_header>
  <id_info>
    <org_study_id>ETCO2-MDS</org_study_id>
    <nct_id>NCT04549623</nct_id>
  </id_info>
  <brief_title>End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography</brief_title>
  <official_title>The Effect of A Novel End-Tidal Carbon Dioxide Monitoring Device for Sedation During Endoscopic Ultrasonography-Guided Fine Needle Aspiration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changhai Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changhai Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To meet the needs of both operators and patients, moderate and deep sedation has been widely&#xD;
      used in digestive endoscopy, which is invasive and painful. With its pleasant effects,&#xD;
      sedation has complications nevertheless. And respiratory depression is the most common one,&#xD;
      which makes respiratory monitoring significant. SpO2 and respiratory motion are regularly&#xD;
      monitored without satisfying timeliness or sensitivity. Capnography with current device is&#xD;
      only able to detect either oral or nasal breathing. The present study was designed to test&#xD;
      the effect of the investigator's modified End-Tidal Carbon Dioxide (ETCO2) monitoring device&#xD;
      for sedation during endoscopic ultrasonography-guided fine needle aspiration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 27, 2020</start_date>
  <completion_date type="Anticipated">February 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peripheral oxygen saturation</measure>
    <time_frame>Across the sedation, assessed up to 2 hours</time_frame>
    <description>Peripheral oxygen saturation is measured by pulse oximetry and hypoxemia is defined as SpO2≤91%</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial pO2 and pCO2</measure>
    <time_frame>30 minutes after initiation of the sedation</time_frame>
    <description>The results of arterial blood gas measurements including partial pressure of oxygen (pO₂) and carbon dioxide (pCO₂)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The numbers of the times of body movement</measure>
    <time_frame>From the completion of sedation to the completion of endosonography procedure, assessed up to 2 hours</time_frame>
    <description>The numbers of the times of any body movement across the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of hypertension and hypotension</measure>
    <time_frame>From the completion of sedation to the completion of endosonography procedure, assessed up to 2 hours</time_frame>
    <description>Hypertension or hypotension is defined as an increase or decrease in systolic blood pressure ≥20% compared to baseline values</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recovery time</measure>
    <time_frame>After termination of the sedation medication, assessed up to 2 hours</time_frame>
    <description>Duration of the recovery from sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total dosage of propofol</measure>
    <time_frame>Across the sedation, assessed up to 2 hours</time_frame>
    <description>The patients are induced with 1.5~2.5mg/kg and maintained with 6~10mg/(kg•h) propofol. A propofol bolus dose range 0.2~0.5 mg/kg will be administered when needed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction score of the patients and endosonographers</measure>
    <time_frame>Across the procedure, assessed up to 2 hours</time_frame>
    <description>Satisfaction score of the patients and endosonographers regarding to the sedation quality measured by a 0-100 visual analogue scale (VAS). 100 refers to the highest satisfaction degree while 0 refers to the worst satisfaction degree.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Endoscopic Ultrasonography</condition>
  <condition>Sedation</condition>
  <condition>Monitoring</condition>
  <arm_group>
    <arm_group_label>Group ETCO2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Novel end-tidal carbon dioxide monitoring device is used for sedation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group Reg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peripheral oxygen saturation (SpO2) and respiratory motion are regularly monitored during sedation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Novel end-tidal CO2 monitoring device</intervention_name>
    <description>Apart from SpO2 and respiratory motion monitoring, the EtCO2 monitoring device is used to detect CO2 from nose and mouth simultaneously.</description>
    <arm_group_label>Group ETCO2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SpO2 and respiratory motion monitoring</intervention_name>
    <description>Finger SpO2 and ECG-based respiratory motion monitoring are used during operation.</description>
    <arm_group_label>Group Reg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled for ultrasonography-guided fine needle aspiration&#xD;
&#xD;
          -  Adult patients aged 18 to 65 years&#xD;
&#xD;
          -  American Society of Anesthesiologists (ASA) Physical Status Classification I-III&#xD;
&#xD;
          -  Subjects provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Full stomach or upper gastrointestinal tract obstruction&#xD;
&#xD;
          -  Baseline pulse oximetric saturation (SpO2) &lt;95% while breathing room air&#xD;
&#xD;
          -  Obesity （BMI≥28kg/m2）or anticipated difficult airway&#xD;
&#xD;
          -  Cardiovascular or cerebrovascular events within 3 months&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Chronic opioid user&#xD;
&#xD;
          -  Allergic to anesthetics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jia-feng Wang, MD</last_name>
    <phone>+862131161869</phone>
    <email>jfwang@smmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Faculty of Anesthesiology, Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jia-feng Wang, M.D.</last_name>
      <phone>+86-21-31161853</phone>
      <email>jfwang@smmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Jia-feng Wang, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>September 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>October 10, 2020</last_update_submitted>
  <last_update_submitted_qc>October 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Changhai Hospital</investigator_affiliation>
    <investigator_full_name>Jia-feng Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

